NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
Updated: Feb 6
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
Minimal Residual Disease (MRD) testing by Clonoseq will be performed in the peripheral blood of the patients at the same time points that MRD testing will be done in the bone marrow in addition to at 6 and 18 months.
Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Adaptive Biotechnologies
ClinicalTrials.gov Identifier: NCT05172596
Official Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
First Posted : March 9, 2022
Click here to see details on ClinicalTrials.gov
Other: Autologous Stem Cell Transplant
Drug: Immunomodulatory Agent
Drug: Proteasome Inhibitor
Location:
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States, 33612